Taro Lidocaine Ointment 5% recalled for failed strength specifications
Taro Pharmaceuticals is recalling one lot of Lidocaine Ointment USP 5% because testing found the active ingredient strength was outside acceptable limits. The affected lot was identified during long-term stability testing. No injuries have been reported.
From the FDA notice · Read the official notice ↗ · All Sun Pharmaceutical recalls
What to do
- Check if you have lot #AD48154 with expiration date 4/30/2027
- Do not use this ointment; contact your pharmacy or healthcare provider for a replacement
- Return the product to your pharmacy
Is yours affected?
Compare your label or packaging with the recalled product.
- Product
- Lidocaine Ointment USP, 5%, Speermint Flavor, 50 g Jar, Rx only, Mfd. by: Taro Pharmaceuticals Inc., Brampton, Ontario, L6T1C, Canada, Dist By: Taro Pharmaceuticals U.S.A. Inc. Hawthorne NY 70532 NDC: 51672-3008-5
- Sold in
- Nationwide
- Made for
- All ages (0 months and older)
Details
- Units affected
- 65,328 50g jars
- Illnesses reported
- None reported
- Manufactured in
- 3 Skyline Dr, N/A, Hawthorne, NY, United States
- Classification
- Class II
- Recall number
- D-0848-2026
In the FDA's words
- Description
- Lidocaine Ointment USP, 5%, Speermint Flavor, 50 g Jar, Rx only, Mfd. by: Taro Pharmaceuticals Inc., Brampton, Ontario, L6T1C, Canada, Dist By: Taro Pharmaceuticals U.S.A. Inc. Hawthorne NY 70532 NDC: 51672-3008-5 Failed Content Uniformity Specifications. Out of Specification for Assay during analysis at the 24- month long term stability station, at (25¿C,60%RH). Lot # AD48154, Exp: 4/30/2027. Distribution: Nationwide in the USA Affected quantity: 65,328 50g jars
- Hazard
- Failed Content Uniformity Specifications. Out of Specification for Assay during analysis at the 24- month long term stability station, at (25¿C,60%RH).